Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials

A standard systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) is yet to be identified. Sorafenib has been developed for the treatment of solid tumors, including breast cancer, as an oral multikinase inhibitor with antiangiogenic a...

Descripción completa

Detalles Bibliográficos
Autores principales: TAN, QI-XING, QIN, QING-HONG, LIAN, BIN, YANG, WEI-PING, WEI, CHANG-YUAN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991527/
https://www.ncbi.nlm.nih.gov/pubmed/24940450
http://dx.doi.org/10.3892/etm.2014.1603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991527/
https://www.ncbi.nlm.nih.gov/pubmed/24940450
http://dx.doi.org/10.3892/etm.2014.1603

Ejemplares similares